Seattle Genetics reports Q4 EPS (75c), consensus (43c)

Reports Q4 revenue $174.5M, consensus $163.71M.
https://thefly.com/landingPageNews.php?id=2861241

Portola Pharmaceuticals announces results from ANNEXA-4 trial

Portola Pharmaceuticals announced full results from ANNEXA-4, the company’s Phase 3b/4 trial of its Factor Xa inhibitor antidote Andexxa, in patients experiencing acute major bleeding while taking a Factor Xa inhibitor. Data are being presented as a late-breaking oral presentation at the International Stroke Conference and published simultaneously online by The New England Journal of Medicine. Full data from 352 patients showed that Andexxa rapidly and significantly reversed anti-Factor Xa activity when administered as a bolus and sustained this reversal when followed by a 120-minute infusion. Anti-Factor Xa activity is a measure of the anticoagulant activity of apixaban, rivaroxaban, edoxaban and enoxaparin, the anticoagulants studied in ANNEXA-4. Among all 352 patients, 64% were treated for intracranial hemorrhage, or ICH, and 26% were treated for a gastrointestinal bleed. Of those evaluated for efficacy 82% achieved excellent or good hemostasis over the 12-hour period following treatment with Andexxa, as determined by an independent adjudication committee. Within 30 days of enrollment, thrombotic events occurred in 34 patients and death occurred in 49 patients, consistent with previous ANNEXA-4 trial results and with the high background thrombotic risk of the enrolled patient population. The majority of thrombotic events occurred in patients who delayed or did not re-start anticoagulation therapy with a Factor Xa inhibitor during the follow-up period. Among the 100 patients who re-started oral anticoagulation therapy, no thrombotic events were observed. Two patients experienced an infusion reaction and none developed antibodies to Factor Xa or Factor X or neutralizing antibodies to Andexxa.
https://thefly.com/landingPageNews.php?id=2861271

Twist Bioscience reports Q4 EPS ($1.18), consensus (85c)

Reports Q4 revenue $11.5M, consensus $9.73M.
https://thefly.com/landingPageNews.php?id=2861369

Solid Biosciences rating change at SVB Leerink

Solid Biosciences downgraded to Market Perform from Outperform at SVB Leerink. SVB Leerink analyst Joseph Schwartz downgraded Solid Biosciences to Market Perform and cut his price target for the shares to $8 from $50.
https://thefly.com/landingPageNews.php?id=2861437

Arvinas announces poster presentation of ARV-110 at ASCO GU

Arvinas announced that it will present a poster at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place February 14-16 in San Francisco. The presentation will highlight the company’s lead product candidate, ARV-110, an oral androgen receptor-targeted PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate cancer. ARV-110 employs Arvinas’ proprietary PROTAC protein degradation technology.
https://thefly.com/landingPageNews.php?id=2861451

Crispr Therapeutics initiated at BTIG

Crispr Therapeutics initiated with a Buy at BTIG. BTIG analyst Amanda Murphy initiated Crispr Therapeutics with a Buy rating and $43 price target. Murphy sees Crispr as a front runner in the allogeneic pack, with its budding CAR-T pipeline. The analyst believes CTX001 represents under 5% of that price target, while the CAR-T franchise represents roughly 35%, and that the largest contribution comes from the value of the company’s underlying platform, which accounts for slightly under 50% of the price target.
https://thefly.com/landingPageNews.php?id=2861455

Editas Medicine initiated at BTIG

Editas Medicine initiated with a Buy at BTIG. BTIG analyst Amanda Murphy initiated Editas Medicine with a Buy rating and $30 price target. Murphy sees Editas having the broadest CRISPR toolbox, noting that “with its IP portfolio, Editas can target ten times as many sites in the genome relative to wild-type spCas9 and roughly 95% of the human genome in total.”
https://thefly.com/landingPageNews.php?id=2861457